Elite Pharmaceuticals, Inc.
ELTP
Rank in Stocks
#15569
Elite Pharmaceuticals, Inc. (ELTP) is a specialized pharmaceutical company... Elite Pharmaceuticals, Inc. (ELTP) is a specialized pharmaceutical company focused on the creation and manufacturing of generic medications, as well as oral, controlled-release drug formulations. Its business activities are primarily divided into two segments: Abbreviated New Drug Applications (ANDAs) for generic products and New Drug Applications (NDAs) for branded pharmaceuticals. The company's extensive product line includes drugs that it either owns, licenses, or produces through contract manufacturing. This portfolio features a variety of generic and oral-dose pharmaceutical products designed to address diverse medical needs. For instance, it offers Phentermine HCl 37.5mg tablets, marketed under the Adipex-P brand, and Phendimetrazine Tartrate 35mg tablets, known as Bontril, both utilized in bariatric medicine. Its offerings also extend to Naltrexone HCl 50mg tablets (Revia brand) for pain management, and Isradipine 2.5mg and 5mg capsules for cardiovascular conditions. Elite Pharmaceuticals further supplies various strengths of Oxycodone HCl immediate release tablets (5mg, 10mg, 15mg, 20mg, and 30mg) under the Roxycodone brand for pain relief, as well as Trimipramine Maleate Immediate Release antidepressant capsules (Surmontil brand). For central nervous system disorders, the company provides Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, and Amphetamine Sulfate Immediate Release tablets, commonly associated with the Adderall brand. Additionally, its products include Dantrolene Sodium capsules (Dantrium brand) for muscle relaxation, SequestOX (an immediate-release Oxycodone formulation combined with Naltrexone), Loxapine Succinate capsules (Loxapine brand) for antipsychotic treatment, and a combination of Acetaminophen and Codeine Phosphate for managing mild to moderate pain, alongside various antibiotic products. Beyond its own product portfolio, Elite Pharmaceuticals also undertakes contract manufacturing of controlled-release products for external parties, covering therapeutic areas such as pain, allergies, bariatrics, and infections. The company is actively engaged in developing a new generation of opioid products specifically engineered to deter abuse. Established in 1997, Elite Pharmaceuticals, Inc. maintains its corporate headquarters in Northvale, New Jersey.
Share Price
$0.237
Last synced: 2026-11-09
Market Cap
$255.28M
Change (1 day)
-1.25%
Change (1 year)
-63.31%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Elite Pharmaceuticals, Inc. (ELTP)
Category
Healthcare
Operating Margin for Elite Pharmaceuticals, Inc. (ELTP)
Operating Margin as of November 2026 TTM: 25.38%
According to Elite Pharmaceuticals, Inc.'s latest financial reports, its current operating margin (TTM) is 25.38%. At the end of 2025 the company had an operating margin of 23.32%.
Operating Margin history for Elite Pharmaceuticals, Inc. from 2000 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 25.38% | 8.83% |
| 2025 | 23.32% | 22.41% |
| 2024 | 19.05% | 221.25% |
| 2023 | 5.93% | -62.28% |
| 2022 | 15.72% | 89.63% |
| 2021 | 8.29% | -165.28% |
| 2020 | -12.70% | -89.50% |
| 2019 | -121.01% | -0.28% |
| 2018 | -121.35% | 59.00% |
| 2017 | -76.32% | 14.70% |
| 2016 | -66.54% | -79.78% |
| 2015 | -329.14% | 186.63% |
| 2014 | -114.83% | 150.01% |
| 2013 | -45.93% | -43.37% |
| 2012 | -81.11% | 290.70% |
| 2011 | -20.76% | -64.15% |
| 2010 | -57.90% | -79.39% |
| 2009 | -280.91% | -52.56% |
| 2008 | -592.09% | -22.58% |
| 2007 | -764.77% | -29.88% |
| 2006 | -1,090.71% | -33.07% |
| 2005 | -1,629.72% | -10.44% |
| 2004 | -1,819.75% | 222.90% |
| 2003 | -563.57% | 367.96% |
| 2002 | -120.43% | -95.12% |
| 2001 | -2,468.76% | -91.65% |
| 2000 | -29,562.38% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 19.41% | -99.24% |
DE
|
|
| 19.68% | -99.22% |
DE
|
|
| 13.26% | -99.48% |
JP
|
|
| 17.08% | -99.33% |
CH
|
|
| 14.92% | -99.41% |
IL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Elite Pharmaceuticals, Inc.'s operating margin
What is Elite Pharmaceuticals, Inc.'s operating margin?
Elite Pharmaceuticals, Inc.'s operating margin is 25.38%, as of Nov 2026.
What was Elite Pharmaceuticals, Inc.'s operating margin in 2025?
In 2025, Elite Pharmaceuticals, Inc.'s operating margin was 23.32%, compared with 19.05% in 2024.
How has Elite Pharmaceuticals, Inc.'s operating margin changed since 2020?
From 2020 to 2025, Elite Pharmaceuticals, Inc.'s operating margin was highest in 2025 (23.32%) and lowest in 2020 (-12.70%).
How does Elite Pharmaceuticals, Inc.'s operating margin compare with similar companies?
Elite Pharmaceuticals, Inc.'s operating margin (25.38%) is higher than that of all 5 similar companies listed above. The highest among them is Merck KGaA, with 19.68%.